Endpoints News 生物医药· ENDPOINTS·· 2026-10-12AI 评分33
Mirum Pharmaceuticals的Livmarli在超罕见肝病晚期试验中显示疗效;First Tracks在乳糜泻领域取得进展
Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac
AI 导读
Mirum Pharmaceuticals的Ileal bile acid transporter inhibitor Livmarli在超罕见肝病的晚期临床试验中显著降低了胆汁淤积性瘙痒。First Tracks在乳糜泻相关领域也取得了积极结果。
正文
Mirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news